Wall Street brokerages expect that Xenon Pharmaceuticals Inc (NASDAQ:XENE) will post earnings of ($0.47) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Xenon Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.48) and the highest is ($0.45). Xenon Pharmaceuticals reported earnings per share of ($0.43) in the same quarter last year, which would suggest a negative year-over-year growth rate of 9.3%. The company is scheduled to issue its next quarterly earnings results on Tuesday, November 6th.
According to Zacks, analysts expect that Xenon Pharmaceuticals will report full-year earnings of ($1.33) per share for the current fiscal year, with EPS estimates ranging from ($1.59) to ($0.96). For the next financial year, analysts anticipate that the company will report earnings of ($1.73) per share, with EPS estimates ranging from ($1.91) to ($1.52). Zacks’ EPS calculations are an average based on a survey of research firms that cover Xenon Pharmaceuticals.
Xenon Pharmaceuticals (NASDAQ:XENE) last issued its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.04.
XENE stock traded up $0.04 on Friday, hitting $10.66. 49,500 shares of the company were exchanged, compared to its average volume of 175,525. Xenon Pharmaceuticals has a twelve month low of $2.10 and a twelve month high of $15.92. The company has a debt-to-equity ratio of 0.41, a quick ratio of 20.83 and a current ratio of 20.83. The firm has a market capitalization of $198.58 million, a price-to-earnings ratio of -6.17 and a beta of 0.87.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Bank of Montreal Can grew its stake in Xenon Pharmaceuticals by 433.3% during the third quarter. Bank of Montreal Can now owns 11,721 shares of the biopharmaceutical company’s stock worth $155,000 after buying an additional 9,523 shares during the period. OppenheimerFunds Inc. boosted its stake in shares of Xenon Pharmaceuticals by 104.3% in the second quarter. OppenheimerFunds Inc. now owns 22,481 shares of the biopharmaceutical company’s stock valued at $207,000 after purchasing an additional 11,476 shares during the period. Kovack Advisors Inc. purchased a new position in shares of Xenon Pharmaceuticals in the second quarter valued at $113,000. Spark Investment Management LLC boosted its stake in shares of Xenon Pharmaceuticals by 105.5% in the second quarter. Spark Investment Management LLC now owns 26,100 shares of the biopharmaceutical company’s stock valued at $240,000 after purchasing an additional 13,400 shares during the period. Finally, Elmwood Wealth Management Inc. boosted its stake in shares of Xenon Pharmaceuticals by 100.0% in the second quarter. Elmwood Wealth Management Inc. now owns 37,458 shares of the biopharmaceutical company’s stock valued at $264,000 after purchasing an additional 18,729 shares during the period. Institutional investors own 47.13% of the company’s stock.
Xenon Pharmaceuticals Company Profile
Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. The company uses Extreme Genetics, a core enabling discovery platform for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies.
Featured Story: What is a Call Option?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.